Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge

After a bruising financial third quarter in which net quarterly profit plunged 65%, Lupin reported “a successful outcome” for clinical trials of its rheumatoid arthritis drug etanercept, its first biosimilar product for the global market.